Adtalem Global Education Inc, the largest healthcare educator in the United States, announced the completion of its $150 million share repurchase program, under which the company bought back approximately 1.6 million shares. In addition, the Board of Directors has approved a new $750 million share repurchase authorization effective through December 2028. The new three-year program reflects the confidence of management and the Board in Adtalem’s strategic direction, its solid financial position, and its ability to generate strong cash flow while continuing to invest in growth initiatives.
Health Technology Insights: Appointment of Francis Van Parys as Chief Executive Officer
Steve Beard, chairman and chief executive officer of Adtalem Global Education, said that the company’s operational performance continues to produce significant cash flow, providing the flexibility to pursue growth opportunities while returning value to shareholders in a tax-efficient manner. He explained that the new repurchase authorization demonstrates a disciplined and return-focused approach to capital allocation. Beard added that demand for Adtalem’s programs, which prepare the healthcare workforce that the nation needs, is increasing, and the company is well positioned to capitalize on these opportunities while rewarding shareholders.
Health Technology Insights: Genmab Shares Phase 3 Data on EPKINLY Combo for FL Patients
Since February 2022, Adtalem has returned $913 million to shareholders through the repurchase of 17.2 million shares at an average price of $52.95 per share, resulting in a 30 percent reduction in shares outstanding compared with the base level as of February 1, 2022. As of December 10, 2025, the company has 34.9 million shares of common stock outstanding. In addition, Adtalem has strengthened its balance sheet, reducing debt by $1.1 billion since the closing of the Walden University acquisition on August 31, 2021, leaving a total debt of $508.4 million as of October 31, 2025.
Repurchases under the new authorization may be conducted from time to time through a variety of methods, including open market purchases or privately negotiated transactions, all in compliance with Securities and Exchange Commission rules and other applicable regulations. The timing, price, and volume of repurchases will depend on stock market conditions, economic factors, and other relevant considerations.
Health Technology Insights: Incyte Reports Positive INCA033989 Data in Myelofibrosis
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
